<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897127</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG 30-18</org_study_id>
    <nct_id>NCT03897127</nct_id>
  </id_info>
  <brief_title>Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics</brief_title>
  <official_title>Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a randomized, open-label phase III study comparing CPX-351 vs conventional
      intensive induction and consolidation chemotherapy in patients with newly diagnosed AML and
      intermediate- or adverse-risk genetics (according to 2017 ELN criteria), including AML with
      myelodysplasia-related changes (AML-MRC) and therapy-related AML according to the World
      Health Organization (WHO) classification. Event-free survival (EFS) will be the primary
      endpoint as defined by standard criteria (Döhner 2017).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death (CID)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of objective response</measure>
    <time_frame>2 months</time_frame>
    <description>complete remission [CR], CR with incomplete hematologic recovery [CRi], CR without minimal residual disease [CRMRD-]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 months</time_frame>
    <description>Incidence and intensity of adverse events (AEs) according to Common Terminology Criteria for Adverse Events (CTCAE) version v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Analysis of rate of response according to cytogenetic and molecular genetic changes</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Overall survival according to cytogenetic and molecular genetic changes</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Relapse-free survival according to cytogenetic and molecular genetic changes</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Event-free survival according to cytogenetic and molecular genetic changes</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Overall Survival according to Minimal Residual Disease results during and after treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Event-free Survival according to Minimal Residual Disease results during and after treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL NCI PRO-CTCAE (National Cancer Institute) Patient Reported Outcomes Common Terminology Criteria for Adverse Events questionnaire)</measure>
    <time_frame>2 years</time_frame>
    <description>PRO-CTCAE responses are scored from 0 to 4, whereas lower values represent a better outcome. For this trial, the burden of symptoms that will be captured by this questionnaire comprises nausea, diarrhea, rash, and alopecia.</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL EORTC QLQ-FA12</measure>
    <time_frame>2 years</time_frame>
    <description>The EORTC QLQ-FA12 module complements the core EORTC QLQ-C30 questionnaire regarding fatigue. . Each item can be scored in four dimension on a scale from 1 to 4 with higher scores indicating worse symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL EORTC QLQ-C30 (Core Quality of Life Questionnaire developed by European Organization for Research and Treatment of Cancer )</measure>
    <time_frame>2 years</time_frame>
    <description>The EORTC QLQ-C30 subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of hospitalization including admissions at intensive care unit (ICU)</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Reasons for hospitalization</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>days of hospitalization by treatment setting</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>rate of use of anti-infectives and other medications, e.g. against nausea or vomiting</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>additional therapies administered</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>place of chemotherapy administration (inpatient vs outpatient setting)</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>duration of administration</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>number of outpatient visits</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of salvage therapies</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">593</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Induction therapy: 200 mg/m2 i.v. (continuously) d1-7
Consolidation therapy:
Patients age 18-60 years
o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3
Patients age &gt;60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3</description>
    <arm_group_label>Standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3</description>
    <arm_group_label>Standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>Induction 1:
Patients age 18-60 years
o CPX-351 55 mg/m2 daunorubicin / 125 mg/m2 cytarabine [125 U/m²] i.v. (90 min) d1,3,5
Patients age &gt;60 years o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3,5
Induction 2:
• Patients age 18-60 years
CPX-351 55 mg/m2 daunorubicin / 125 mg/m2 cytarabine [125 U/m²] i.v. (90 min) d1,3
• Patients age &gt;60 years
CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3
Consolidation therapy:
o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine [65 U/m²] i.v. (90 min) d1,3</description>
    <arm_group_label>Investigational arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly diagnosed AML and intermediate- or adverse-risk genetics
             (according to 2017 ELN criteria [Appendix B]), including AML with
             myelodysplasia-related changes (AML-MRC) and therapy-related AML according to the
             World Health Organization (WHO) classification

          2. Age ≥ 18 years, no upper age limit

          3. Patient considered eligible for intensive chemotherapy

          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at Screening (for
             younger patients [18-60 years of age] ≤ 1)

          5. Genetic assessment in AMLSG central laboratory

          6. Adequate renal function as evidenced by serum creatinine ≤ 2.0 × ULN or creatinine
             clearance &gt;40 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR)

          7. Adequate hepatic function as evidenced by:

               -  Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) unless considered due
                  to Gilbert's disease, or leukemic involvement following approval by the
                  Coordinating Investigator or Trial Coordinator

               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline
                  phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic involvement
                  following approval by the Coordinating Investigator or Trial Coordinator

          8. No prior chemotherapy for acute leukemia except hydroxyurea for up to 7 days during
             the diagnostic screening phase for the control of peripheral leukemic blasts in
             patients with leukocytosis (e.g., white blood cell [WBC] counts &gt;30x109/l); prior
             treatment of myelo-dysplastic syndrome with hypomethylating agents is allowed

          9. Non-pregnant and non-nursing women of childbearing potential (WOCBP) must have a
             negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL
             within 72 hours prior to randomization (&quot;Women of childbearing potential&quot; is defined
             as a sexually active mature woman who has not undergone a hysterectomy or bilateral
             oophorectomy or who has had menses at any time in the preceding 24 consecutive months)

         10. Female patients of childbearing potential must agree to avoid getting pregnant while
             on therapy and for 6 months after the last dose of CPX-351

         11. Women of childbearing potential must either commit to continued abstinence from
             heterosexual intercourse or apply one highly effective method of birth control (such
             as IUD, bilateral tubal ligation, or partner's vasectomy) in combination with one
             acceptable method of birth control at the same time (such as hormonal contraception or
             the male partner has to use a latex condom coated with spermicide lubricant or
             combined with spermicide gel or foam) while on therapy and for 6 months after the last
             dose of CPX-351. Hormonal contraception is only a highly effective method of birth
             control in case of combined (estrogen and progestogen containing) associated with
             inhibition of ovulation or progestogen-only hormonal contraception associated with
             inhibition of ovulation is used

         12. Men must use a latex condom coated with a spermicide lubricant or combined with
             spermicide gel or foam during any sexual contact with women of childbearing potential,
             even if they have undergone a successful vasectomy and must agree to avoid to father a
             child (while on therapy and for 6 months after the last dose of CPX-351). In addition,
             their female partners of childbearing potential have to use a highly effective method
             of birth control

         13. Able to understand and willing to sign an informed consent form (ICF)

        Exclusion Criteria:

          1. AML with favorable-risk genetics according to 2017 ELN criteria [Appendix B]:

               -  AML with t(8;21)(q22;q22.1), RUNX1-RUNX1T1

               -  AML with inv(16)(p13.1q22)/t(16;16)(p13.1;q22), CBFB-MYH11

               -  AML with mutated NPM1 without FLT3-ITD or with FLT3-ITDlow

               -  AML with biallelic CEBPA mutation

          2. Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); PML-RARA; or one of the
             other pathognomonic variant chromosomal translocations/ fusion genes

          3. AML with BCR-ABL1

          4. Prior treatment of myelodysplastic syndrome (MDS) with intensive chemotherapy or bone
             marrow transplant with a curative intent

          5. Significant active cardiac disease within 6 months prior to the start of study
             treatment, including New York Heart Association (NYHA) class III or IV congestive
             heart failure; myocardial infarction, unstable angina and/or stroke; severe cardiac
             arrhythmias, or left ventricular ejection fraction (LVEF) &lt;50% by ultrasound obtained
             within 28 days prior to the start of study treatment

          6. Severe obstructive or restrictive ventilation disorder

          7. Uncontrolled infection

          8. Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known
             CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is only
             required, if there is a clinical suspicion of CNS involvement by leukemia during
             screening

          9. Known history of positive test for hepatitis B surface Antigen (HBSAg) or hepatitis C
             antibody or history of positive test for Human Immunodeficiency Virus (HIV)

         10. Patients with a &quot;currently active&quot; second malignancy. Patients are not considered to
             have a currently active malignancy, if they have completed therapy and are considered
             by their physician to be at &lt; 30% risk of relapse within one year. However, subjects
             with the following history/concurrent conditions are allowed:

               -  Basal or squamous cell carcinoma of the skin

               -  Carcinoma in situ of the cervix

               -  Carcinoma in situ of the breast

               -  Incidental histologic finding of prostate cancer

         11. Severe neurological or psychiatric disorder interfering with ability to give an
             informed consent

         12. No consent for registration, storage and processing of the individual disease
             characteristics and course as well as information of the family physician about study
             participation

         13. No consent for biobanking of patient's biological specimens

         14. Current participation in any other interventional clinical study within 30 days before
             the first administration of the investigational product or at any time during the
             study

         15. Patients with prior cumulative anthracycline exposure of daunorubicin (or equivalent)
             can be included but the maximum of daunorubicin (or equivalent) dose of 550 mg/m2 must
             not be exceeded. In patients who received radiation therapy to the mediastinum the
             maximum of daunorubicin (or equivalent) dose of 400 mg/m2 must not be exceeded.

         16. Known or suspected hypersensitivity to cytarabine, daunorubicin or liposomal products
             and/or any excipients

         17. History of Wilson's disease or other copper-metabolism disorder

         18. Receipt of live, attenuated vaccine within 30 days prior to the study inclusion (NOTE:
             Subjects, if enrolled, should not receive live vaccine during the study and until 6
             months after the therapy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Paschka, MD</last_name>
    <phone>0049-731-500</phone>
    <phone_ext>45521</phone_ext>
    <email>peter.paschka@uniklinik-ulm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manfred Welslau, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Simone Liebler, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Scholz, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Annette Dieing, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maike de Witt, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Lore Marretta, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité Berlin ‐ Campus Virchow‐Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jörg Westermann, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Anne Flörcken, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bochum‐Langendreer</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roland Schroers, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Alexander Baraniskin, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Feldmann, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Juliane Klein, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Krauter, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Arne Trummer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen‐Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernd Hertenstein, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephan Kaun, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Bernhard, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephan Schäfer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St.‐Johannes‐Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Darina Kodzhabasheva, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ralf Georg Meyer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Schroeder, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ulrich Germing, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Süd, Ev. Krankenhaus Essen‐ Werden gGmbH</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohammed Wattad, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Peter Reimer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swen Wessendorf, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Rebekka Mannal, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus‐Hospital</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezda Basara, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Helge Menzel, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Rummel, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Alexander Burchardt, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Katholisches Karl‐Leisner‐Klinikum gGmbH, Wilhelm‐Anton‐Hospital gGmbH Goch</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volker Runde, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jörn Westheider, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg‐Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Walter Fiedler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Melanie Janning, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Salwender, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Cord Beeger, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hamm gGmbH</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth Lange, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas Wehler, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andrea Stoltefuß, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Region Hannover ‐ Klinikum Siloah</name>
      <address>
        <city>Hannover</city>
        <zip>30459</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Müller, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Kim Marienhagen, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Daniela Dörfel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felicitas Thol, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Michael Heuser, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>SLK‐Kliniken GmbH Heilbronn</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Lindauer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Uwe Martens, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Marienhospital Herne, Klinikum der Ruhr</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Schultheis, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Dirk Strumberg, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kaiserslautern, Westpfalz‐Klinikum</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerhard Held, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Milena Pfeifer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Ringhoffer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Lukas Kündgen, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Caritas‐Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Kremers, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gero Leonhard-Helmschmidt, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe‐Lemgo</name>
      <address>
        <city>Lemgo</city>
        <zip>32657</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hesse Tanja, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Frank Hartmann, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Heil, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Iordanis Deligiannis, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Mikusko, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Vanja Zeremski, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kühn, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Markus Radsak, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Joachim Tischler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Kai Wille, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katharina Götze, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Isabella Miller, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum, Offenburg‐Gengenbach</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Schwänen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Irmgard Dresel, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jochen Reutschel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pius Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Imme Conradi, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Frank Griesinger, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Südhoff, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thorsten Nitsch, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Heudobler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Simone Thomas, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Schleicher, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Alf Jörg Zerzweck, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Denzlinger, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Lale Kaylkci, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Dietl, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas Kubin, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mutterhaus der Borromäerinnen</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rolf Mahlberg, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stefan Hebel, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Kirchen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Monika Lankeshofer-Loch, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliane Walz, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Dominik Schneidawind, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Paschka, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Verena Gaidzik, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Schwarzwald‐Baar Klinikum Villingen‐ Schwenningen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Graf La Rosée, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Henkes, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silke Schostock, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Blasius Liss, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Peter Paschka</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>CPX-351</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

